Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Fennec Pharmaceuticals Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.335 Good morning, ladies and gentlemen, and welcome to FinEx Pharmaceuticals' second quarter 00:00:04.335 -- 00:00:07.558 2025 Earnings and Corporate Update conference call. 00:00:07.558 -- 00:00:10.321 At this time, all participants are in a listen-only mode. 00:00:10.321 -- 00:00:13.944 Later, we will conduct a question-and-answer session, and instructions on how to participate 00:00:13.944 -- 00:00:18.828 will be given at that time. As a reminder, today's conference is being recorded. 00:00:18.828 -- 00:00:22.171 Now, I would like to turn the conference over to FinEx Chief Financial Officer, Robert 00:00:22.171 -- 00:00:24.171 Andrade. 00:00:24.934 -- 00:00:28.137 Thank you, Operator, and good morning, everyone. 00:00:28.137 -- 00:00:33.295 Thank you for joining us. We are pleased to host Fennec Pharmaceuticals' second quarter 00:00:33.295 -- 00:00:38.463 2025 earnings conference call today, during which we will review 00:00:38.463 -- 00:00:43.952 our financial results as well as provide a general business update. 00:00:43.952 -- 00:00:48.979 Joining me from Fennec this morning is our chief executive officer and board 00:00:48.979 -- 00:00:54.208 member, Jeff Hackman. Before we begin, I would like to remind you that 00:00:54.208 -- 00:00:58.233 during this call, the company will be making forward-looking statements. 00:00:58.233 -- 00:01:03.998 that are subject to risks and uncertainties that may cause actual results to differ 00:01:03.998 -- 00:01:07.641 from the results discussed in the forward-looking statements. 00:01:07.641 -- 00:01:12.646 References to these risks and uncertainties are made in today's press release and disclosed 00:01:12.646 -- 00:01:17.490 in detail in the company's periodic and current event filings with the...